
    
      This is a randomized, placebo-controlled, double-dummy, multi-center study of the safety,
      efficacy and tolerability of SEP-225289 in male and female subjects with MDD. Subjects
      meeting DSM-IV criteria for Melancholic or Atypical Features specifier are eligible for
      participation. The study will consist of a screening period, which may last up to 2 weeks, an
      eight week (56 day) double-blind treatment period, a two week (14 day) wash-out, and a one
      week (7 day) follow up. Total subject participation will be approximately 91 days (13 weeks).
      This study was previously posted by Sepracor Inc. In October 2009, Sepracor Inc. was acquired
      by Dainippon Sumitomo Pharma., and in October 2010, Sepracor Inc's name was changed to
      Sunovion Pharmaceuticals Inc.
    
  